Cardiovascular
Cardiac cell therapy has accumulated years of early and mid-stage research without turning generic regeneration claims into routine treatment. Hypertension and heart failure should never share one undifferentiated offer.
What the registry pattern says
Heart failure has the largest MSC registry footprint in this group (32 query results; 3 recruiting in the stored snapshot). Heart failure has the largest exosome footprint (1). These are query-result counts, not deduplicated patients or proof of benefit.
Look for hard cardiovascular endpoints, background standard care and the exact delivery method; a change in a surrogate imaging measure may not mean fewer admissions or longer survival.
Condition × therapy-class snapshot
| Condition | MSC | MSC recruiting | HSCT-family | Exosomes |
|---|---|---|---|---|
| Arterial Hypertension | 0 | 0 | 0 | 0 |
| Heart failure | 32 | 3 | 13 | 1 |
Source: ClinicalTrials.gov API v2 stored snapshot. Category totals add query results and may contain overlapping studies; use condition pages for interpretation.
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.